Five Prime Therapeutics
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, Five Prime Therapeutics sits in the upper quartile of US sponsors by registered trial count (#1,806 of 15,742 sponsors by registered trial count).
Five Prime Therapeutics: 7 sponsored US clinical trials, none currently recruiting.
Five Prime Therapeutics sponsors 7 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 6 completed. 0 of these trials are in Phase 3-4 (later-stage) and 7 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Advanced Solid Tumors, with 2 trials.
Upper-quartile sponsor footprint
Five Prime Therapeutics sits in the upper quartile of the sponsor corpus (#1,806 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Indexed trials (enrollment closed)
7 total, page 1 of 1
A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 (mFOLFOX6) in Gastric/Gastroesophageal Junction Cancer
NCT03694522
FPA150 in Patients With Advanced Solid Tumors
NCT03514121
A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 in Gastric/Gastroesophageal Cancer
NCT03343301
Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
NCT02526017
Study of Cabiralizumab in Patients With Pigmented Villonodular Synovitis / Diffuse Type Tenosynovial Giant Cell Tumor
NCT02471716
Open-Label, Dose-Finding Study Evaluating Safety and PK of FPA144 in Patients With Advanced Solid Tumors
NCT02318329
Safety Study of FP-1039 To Treat Cancer
NCT00687505
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 6 |
| Phase 2 | 1 |
How the Five Prime Therapeutics early-phase archive is shaped
7 indexed studies, none listed as recruiting (0% open); 6 completed (86%).
Phase mix: 0 late (III/IV) vs 7 early (I/II) (early-phase heavy).
Top condition: Advanced Solid Tumors (2 trials), 9 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Five Prime Therapeutics: archived-pipeline peers nationwide
Peers matched on 7 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Five Prime Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 7 archived trials
- 3M · 7 trials · 0% recruiting
- 4Life Research · 7 trials · 0% recruiting
- 89bio · 7 trials · 29% recruiting
- Abbott Diagnostics Division · 7 trials · 0% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Five Prime Therapeutics page
7 registered trials is a research-attention snapshot, not an endorsement of Five Prime Therapeutics or any single study.
- None of Five Prime Therapeutics's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Advanced Solid Tumors is the condition Five Prime Therapeutics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Advanced Solid Tumors trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Five Prime Therapeutics pipeline card: 7 registered trials from official public datasets.Report a data error.